425: CoreWeave Files SEC Form 425 on Proposed Core Scientific Acquisition

CoreWeave, Inc. has filed a Form 425 with the SEC regarding its proposed acquisition of Core Scientific, Inc., providing essential information for investors and security holders on the transaction.

Summary

• CoreWeave, Inc. filed a Form 425 with the U.S. Securities and Exchange Commission (SEC) on July 8, 2025, in connection with its proposed acquisition of Core Scientific, Inc.
• The filing serves as a communication posted on CoreWeave's X account concerning the acquisition.
• CoreWeave and Core Scientific will file relevant materials with the SEC, including a registration statement on Form S-4 by CoreWeave, which will encompass a proxy statement of Core Scientific and a prospectus of CoreWeave.
• A definitive proxy statement/prospectus will be mailed to stockholders of Core Scientific.
• Investors and security holders are strongly advised to thoroughly read the registration statement, proxy statement/prospectus, and any other relevant documents filed with the SEC before making any voting or investment decisions.
• Information regarding the directors and executive officers of both Core Scientific and CoreWeave, who may be deemed participants in the proxy solicitation, is referenced in their respective prior SEC filings.
• This communication is solely for informational purposes and does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor a solicitation of any vote or approval.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing for a proposed acquisition, indicating progress on the transaction. However, it is heavily weighted with extensive disclaimers and a comprehensive list of potential risks and uncertainties associated with the transaction and future operations, which tempers overall sentiment.

Risks

• The completion of the proposed transaction on anticipated terms, or at all, and the timing of completion, including obtaining required regulatory approvals and Core Scientific stockholder approval.
• Unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, and business and management strategies for the combined company.
• The possibility that any anticipated benefits of the proposed transaction will not be realized or will not be realized within the expected time period.
• The ability of CoreWeave and Core Scientific to successfully integrate their businesses and achieve anticipated synergies and value creation.
• Potential litigation relating to the proposed transaction that could be instituted against CoreWeave, Core Scientific, or their respective directors and officers.
• Disruptions from the proposed transaction harming CoreWeave's or Core Scientific's business, including current plans and operations.
• Diversion of management's time and attention to transaction-related issues.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction.
• Rating agency actions and CoreWeave's and Core Scientific's ability to access shortand long-term debt markets on a timely and affordable basis.
• Legislative, regulatory, and economic developments and actions targeting public companies in the artificial intelligence, power, data center, and crypto mining industries, and changes in relevant laws, regulations, and policies.
• Potential business uncertainty, including the outcome of commercial negotiations and changes to existing business relationships during the pendency of the proposed transaction.
• Certain restrictions during the pendency of the proposed transaction that may impact Core Scientific's ability to pursue certain business opportunities or strategic transactions.
• Acts of terrorism, outbreak of war, hostilities, civil unrest, attacks against CoreWeave or Core Scientific, and other political or security disturbances.
• Dilution caused by CoreWeave's issuance of additional shares of its securities in connection with the proposed transaction.
• The possibility that the transaction may be more expensive to complete than anticipated due to unexpected factors or events.
• The impacts of pandemics or other public health crises, including the effects of government responses on people and economies.
• Global or regional changes in the supply and demand for power and other market or economic conditions that impact demand and pricing.
• Changes in technical or operating conditions, including unforeseen technical difficulties.
• Development delays at CoreWeave and/or Core Scientific data center sites, including any delays in the conversion of such sites from crypto mining facilities to high-performance computing sites.

Future Outlook

The document contains forward-looking statements concerning the consummation of the proposed transaction and its anticipated benefits, including successful business integration, achievement of synergies, future capital expenditures, revenues, expenses, earnings, and the expansion and growth of the combined company's operations. It explicitly states that actual results could differ materially from these forward-looking statements due to various risks and uncertainties, and neither company assumes an obligation to publicly update these statements.

Industry Context

This announcement relates to a significant proposed acquisition within the artificial intelligence, power, data center, and crypto mining industries. The transaction suggests a strategic shift or expansion, particularly for Core Scientific, which has a background in crypto mining, potentially moving towards high-performance computing capabilities under CoreWeave's ownership.

Legal Proceedings

• Potential litigation relating to the proposed transaction that could be instituted against CoreWeave, Core Scientific, or their respective directors and officers.

Stakeholder Impact

• Stockholders of Core Scientific will receive a definitive proxy statement/prospectus and will be required to vote on the proposed transaction.
• CoreWeave's issuance of additional shares in connection with the transaction could cause dilution for existing CoreWeave shareholders.
• The transaction could lead to potential adverse reactions or changes to existing business relationships for both CoreWeave and Core Scientific.
• Management's time and attention for both companies will be diverted to transaction-related issues during the pendency of the acquisition.

Next Steps

• CoreWeave and Core Scientific will file a registration statement on Form S-4, which will include a proxy statement/prospectus, with the SEC.
• A definitive proxy statement/prospectus will be mailed to stockholders of Core Scientific.
• Investors and security holders are urged to read the registration statement, proxy statement/prospectus, and other relevant documents when they become available.
• Additional information regarding the participants in the proxy solicitations and a description of their direct or indirect interests will be contained in the proxy statement/prospectus and other relevant materials filed with the SEC when they become available.

Key Dates

Keywords

CoreWeave, Core Scientific, Acquisition, Merger, SEC Filing, Form 425, S-4, Proxy Statement, Prospectus, Artificial Intelligence, Data Center, Crypto Mining, Corporate Governance, Risk Factors